Download Files:
Narlaprevir
$320 – $1,200
Products Details
Product Description
– Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM[1]. Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease[2]. Narlaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.3 μM[3].
Web ID
– HY-10300
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C36H61N5O7S
References
– [1]Ashok Arasappan, et al. Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS<sub>3</sub> Serine Protease Inhibitor. ACS Med Chem Lett. 2010 Feb 15;1(2):64-9.|[2]X Tong, et al. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS<sub>3</sub> protease. Antimicrob Agents Chemother. 2010 Jun;54(6):2365-70.|[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.
CAS Number
– 865466-24-6
Molecular Weight
– 707.96
Compound Purity
– 98.15
SMILES
– O=S(CC1(NC(N[C@H](C(N2[C@@H]([C@@]3([H])C(C)([C@]3(C2)[H])C)C(N[C@H](C(C(NC4CC4)=O)=O)CCCC)=O)=O)C(C)(C)C)=O)CCCCC1)(C(C)(C)C)=O
Clinical Information
– Launched
Research Area
– Infection
Solubility
– DMSO : ≥ 50 mg/mL
Target
– HCV;HCV Protease;SARS-CoV
Pathway
– Anti-infection;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
